{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "USD", "exchange": "LSE", "shortName": "VIKING THERAPEUTICS INC VIKING ", "longName": "Viking Therapeutics, Inc.", "messageBoardId": "finmb_246791410", "exchangeTimezoneName": "Europe/London", "exchangeTimezoneShortName": "BST", "gmtOffSetMilliseconds": 3600000, "market": "gb_market", "esgPopulated": false, "regularMarketChangePercent": -4.0530205, "regularMarketPrice": 22.0774, "marketState": "CLOSED", "firstTradeDateMilliseconds": 1538982000000, "priceHint": 2, "epsTrailingTwelveMonths": -0.733, "sharesOutstanding": 71459904, "bookValue": 1.69, "fiftyDayAverage": 16.210978, "fiftyDayAverageChange": 5.8664227, "fiftyDayAverageChangePercent": 0.36187965, "twoHundredDayAverage": 9.543472, "twoHundredDayAverageChange": 12.533928, "twoHundredDayAverageChangePercent": 1.3133509, "marketCap": 15866100, "priceToBook": 13.06355, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "tradeable": false, "cryptoTradeable": false, "regularMarketChange": -0.9326, "regularMarketTime": 1683910818, "regularMarketDayHigh": 22.8842, "regularMarketDayRange": "22.0774 - 22.8842", "regularMarketDayLow": 22.0774, "regularMarketVolume": 1572, "regularMarketPreviousClose": 23.01, "bid": 0.0, "ask": 0.0, "fullExchangeName": "LSE", "financialCurrency": "USD", "regularMarketOpen": 22.8842, "averageDailyVolume3Month": 5253, "averageDailyVolume10Day": 3498, "fiftyTwoWeekLowChange": 19.9274, "fiftyTwoWeekLowChangePercent": 9.268558, "fiftyTwoWeekRange": "2.15 - 23.315", "fiftyTwoWeekHighChange": -1.2376003, "fiftyTwoWeekHighChangePercent": -0.05308172, "fiftyTwoWeekLow": 2.15, "fiftyTwoWeekHigh": 23.315, "earningsTimestamp": 1682541000, "earningsTimestampStart": 1690315200, "earningsTimestampEnd": 1690833600, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "symbol": "0VQA.L"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "9920 Pacific Heights Boulevard", "address2": "Suite 350", "city": "San Diego", "state": "CA", "zip": "92121", "country": "United States", "phone": "858 704 4660", "website": "https://www.vikingtherapeutics.com", "industry": "", "sector": "", "longBusinessSummary": "Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TR\u00df), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TR\u00df for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.", "fullTimeEmployees": 22, "companyOfficers": [{"maxAge": 1, "name": "Dr. Brian  Lian Ph.D.", "age": 56, "title": "Pres, CEO & Director", "yearBorn": 1966, "fiscalYear": 2021, "totalPay": {"raw": 872000, "fmt": "872k", "longFmt": "872,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 1414261, "fmt": "1.41M", "longFmt": "1,414,261"}}, {"maxAge": 1, "name": "Mr. Gregory S. Zante", "age": 51, "title": "Chief Financial Officer", "yearBorn": 1971, "fiscalYear": 2021, "totalPay": {"raw": 536000, "fmt": "536k", "longFmt": "536,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Marianne  Mancini", "age": 57, "title": "Chief Operating Officer", "yearBorn": 1965, "fiscalYear": 2021, "totalPay": {"raw": 543000, "fmt": "543k", "longFmt": "543,000"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 372305, "fmt": "372.31k", "longFmt": "372,305"}}, {"maxAge": 1, "name": "Mr. Michael  Morneau", "age": 57, "title": "VP of Fin. & Admin.", "yearBorn": 1965, "fiscalYear": 2018, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Geoffrey E. Barker Ph.D.", "title": "Sr. VP of Pharmaceutical Devel.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 9, "boardRisk": 7, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1640908800, "maxAge": 86400}}], "error": null}}